Summary
We studied the role and clinical implications of preheparin serum lipoprotein lipase mass( preheparin LPL mass). Among hyperlipidemic patients, preheparin LPL mass in type IIa was almost equal to that of normal control, but those in type IV and IIb were significantly lower. In non-insulin dependent diabetes mellitus, preheparin LPL mass was significantly lower than controls. HbAlc was negatively correlated with preheparin LPL mass. An insulin-sensitizer troglitazone administration to noninsulindependent diabetes mellitus patients enhanced preheparin LPL mass and HDL-cholesterol, accompanying with decreases in HbAlc and triglycerides. Bezafibrate administration to type IIb or IV patients decreased triglyceride and increased HDL-cholesterol and preheparin LPL mass also.
These results suggested that preheparin LPL mass was enhanced by the situation in which, lipoprotein lipase production was augmented, and was also enhanced in the situations in which insulin is functioning well. Then, it might be concluded that preheparin LPL mass can be a noble indicator for the amount of LPL functioning in a whole body, even though indirectly.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Reference
Tornvall P, Olivecrona G, Karpe F, Hamsten A, Olivecrona T (1995) Lipoprotein lipase mass and activity in plasma and their increase after heparin are separate parameters with different relations to plasma lipoproteins. Athero Throm Vasc Biol. 115: 1086–1093
Watanabe H, Miyashita Y, Murano T, Hire Y, Itoh Y, Shirai K(1999) Preheparin lipoprotein lipase mass level; the effects of age, gender, and types of hyperlipidemias. Atherosclerosis 145: 45–50
Kobayashi J, Takahashi K, Tashiro J, Shirai K, Saito Y (1994) Effect of treatment with bezafibrate on lipoprotein lipase activity and mass in patients with hypertriglyceridemia. Arznei mittelforshung 44(2): 145–148
Shirai K, Itoh Y, Sasaki, H, Totsuka M, Murano T, Watanabe H, Miyashita Y (1999) The effect of insulin sensitizer troglytazone on lipoproteins lipase mass in preheparin serum. Diabetes Res Clin. Practice (in press)
Kobayashi J, Hashimoto H, Fukamachi I, Tashiro J, Shirai K, Saito Y, Yoshida S (1993) Lipoprotein lipase mass and activity in severe hypertriglyceridemia. Clin Chime Acta 216: 113–123
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer-Verlag Tokyo
About this paper
Cite this paper
Shirai, K., Murano, T., Watanabe, H., Miyashita, Y., Itoh, Y., Totsuka, M. (2000). Preheparin Lipoprotein Lipase Mass Might Reflect the Amount of Working Lipoprotein Lipase in the Whole Body. In: Kita, T., Yokode, M. (eds) Lipoprotein Metabolism and Atherogenesis. Springer, Tokyo. https://doi.org/10.1007/978-4-431-68424-4_9
Download citation
DOI: https://doi.org/10.1007/978-4-431-68424-4_9
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-68426-8
Online ISBN: 978-4-431-68424-4
eBook Packages: Springer Book Archive